Literature DB >> 25277161

Adjustment of endogenous concentrations in pharmacokinetic modeling.

Alexander Bauer1, Martin J Wolfsegger.   

Abstract

PURPOSE: Estimating pharmacokinetic parameters in the presence of an endogenous concentration is not straightforward as cross-reactivity in the analytical methodology prevents differentiation between endogenous and dose-related exogenous concentrations. This article proposes a novel intuitive modeling approach which adequately adjusts for the endogenous concentration.
METHODS: Monte Carlo simulations were carried out based on a two-compartment population pharmacokinetic (PK) model fitted to real data following intravenous administration. A constant and a proportional error model were assumed. The performance of the novel model and the method of straightforward subtraction of the observed baseline concentration from post-dose concentrations were compared in terms of terminal half-life, area under the curve from 0 to infinity, and mean residence time.
RESULTS: Mean bias in PK parameters was up to 4.5 times better with the novel model assuming a constant error model and up to 6.5 times better assuming a proportional error model.
CONCLUSIONS: The simulation study indicates that this novel modeling approach results in less biased and more accurate PK estimates than straightforward subtraction of the observed baseline concentration and overcomes the limitations of previously published approaches.

Mesh:

Year:  2014        PMID: 25277161     DOI: 10.1007/s00228-014-1759-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Role of baseline parameters in determining indirect pharmacodynamic responses.

Authors:  Y N Sun; W J Jusko
Journal:  J Pharm Sci       Date:  1999-10       Impact factor: 3.534

2.  Consideration of endogenous backgrounds in pharmacokinetic analyses: a simulation study.

Authors:  F Schindel
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

3.  Approaches to handling pharmacodynamic baseline responses.

Authors:  Chantaratsamon Dansirikul; Hanna E Silber; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-04-30       Impact factor: 2.745

4.  Methods of utilizing baseline values for indirect response models.

Authors:  Sukyung Woo; Dipti Pawaskar; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-08-21       Impact factor: 2.745

5.  Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production.

Authors:  N Hayashi; H Kinoshita; E Yukawa; S Higuchi
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

  5 in total
  4 in total

1.  Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease.

Authors:  Laura H Bukkems; Jessica M Heijdra; Nico C B de Jager; Hendrika C A M Hazendonk; Karin Fijnvandraat; Karina Meijer; Jeroen C J Eikenboom; Britta A P Laros-van Gorkom; Frank W G Leebeek; Marjon H Cnossen; Ron A A Mathôt
Journal:  Blood Adv       Date:  2021-03-09

2.  SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.

Authors:  Andreas Tiede; Geoffrey Allen; Alexander Bauer; Pratima Chowdary; Peter Collins; Brahm Goldstein; Hongyu Jeanne Jiang; Kathleen Kӧck; István Takács; Margarita Timofeeva; Martin Wolfsegger; Shouryadeep Srivastava
Journal:  Haemophilia       Date:  2019-11-28       Impact factor: 4.287

3.  Selective human factor VIII activity measurement after analytical in-line purification.

Authors:  Andrea Engelmaier; Gerald Schrenk; Manfred Billwein; Herbert Gritsch; Christoph Zlabinger; Alfred Weber
Journal:  Res Pract Thromb Haemost       Date:  2022-10-13

Review 4.  Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.

Authors:  Tim Preijers; Lisette M Schütte; Marieke J H A Kruip; Marjon H Cnossen; Frank W G Leebeek; Reinier M van Hest; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.